NASDAQ$RPRX
Royalty Pharma PLC · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Royalty Pharma reported strong Q1 2022 results with a 15% increase in Adjusted Cash Receipts and reaffirmed 2022 guidance.
Royalty Pharma reported a decrease in net cash provided by operating activities to $460 million, while total income and other revenues decreased 2% to $562 million. However, Adjusted Cash Receipts increased 15% to $605 million and Adjusted EBITDA grew 15% to $556 million. The company reaffirmed its 2022 Adjusted Cash Receipts guidance of $2,225 million to $2,300 million.
- Adjusted Cash Receipts increased 15% to $605 million, driven by cystic fibrosis franchise, Tysabri and recent royalty acquisitions.
- Adjusted EBITDA grew 15% to $556 million, driven by strong growth in Adjusted Cash Receipts.
- Announced transactions of up to $450 million in Q1 2022, including an expanded partnership with Cytokinetics.
- 2022 guidance reaffirmed: Adjusted Cash Receipts expected to be $2,225 to $2,300 million.
Headline financials
Revenue & EPS history
Royalty Pharma · Revenue · Quarterly
$562M
Revenue by segment
Royalty Pharma · $626M total across 11 segments · Q1 2022
- Cystic Fibrosis Franchise$202M+21.0%32.3%
- Tysabri$97M+11.5%15.5%
- Other Products$89M+1.1%14.2%
- Imbruvica$87M-2.2%13.9%
- Promacta$48M+9.1%7.7%
- Xtandi$43M+4.9%6.9%
- Tremfya$28M—4.5%
- Cabometyx/Cometriq$13M—2.1%
- Evrysdi$9M+350.0%1.4%
- Erleada$5M+66.7%0.8%
- Trodelvy$5M+66.7%0.8%
Forward guidance
Royalty Pharma reaffirmed its 2022 Adjusted Cash Receipts guidance of $2,225 million to $2,300 million, excluding new transactions announced after the date of this release.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
-0.6%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+0.9%
Avg return
30 days after
43%
10 / 23 earnings
Positive
+6.8%
Q3 2025
Best reaction
-8.1%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -1.0% | +2.4% | +10.7% | |
| Q4 2025 | +0.1% | +2.2% | +3.3% | |
| Q3 2025 | +6.8% | +1.8% | +5.0% | |
| Q1 2025 | +0.9% | +0.2% | +3.1% | |
| Q4 2024 | +1.7% | +2.0% | +3.0% | |
| Q3 2024 | -3.7% | -4.3% | -5.9% | |
| Q2 2024 | -3.6% | -1.4% | +5.3% | |
| Q1 2024 | +0.4% | +0.3% | -1.9% | |
| Q4 2023 | +2.1% | +3.4% | +2.7% | |
| Q3 2023 | -0.5% | -1.6% | +3.7% | |
| Q2 2023 | -0.9% | -1.1% | -6.4% | |
| Q1 2023 | -4.7% | -2.7% | -2.8% | |
| Q4 2022 | -2.0% | -0.4% | -8.8% | |
| Q3 2022 | +1.6% | +3.7% | -0.1% | |
| Q2 2022 | -0.9% | +1.9% | -1.8% | |
| Q1 2022 | -8.1% | -12.8% | -6.2% | |
| Q4 2021 | +3.6% | +0.8% | +1.7% | |
| Q3 2021 | +1.5% | +5.3% | -4.6% | |
| Q2 2021 | +2.7% | +5.0% | +5.6% | |
| Q1 2021 | -2.2% | -1.8% | +12.4% | |
| Q4 2020 | -2.1% | +1.1% | -1.5% | |
| Q3 2020 | -1.6% | +2.8% | +10.3% | |
| Q2 2020 | -3.0% | -4.2% | -5.9% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro